ストックスクリーナーアプリを入手
40.42
0.81%
-0.33
前日終値:
$40.75
開ける：
$40.2
24時間の取引高:
380.69K
Relative Volume:
0.85
時価総額：
$4.99B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+3.35%
1か月 パフォーマンス:
+12.59%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$39.50
$41.19
1週間の範囲:
$37.77
$41.19
52週間の値動き範囲:
$24.51
$41.49
Parabilis Medicines Inc Stock (PBLS) Company Profile
Compare PBLS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
40.42 | 4.89B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Parabilis Medicines Inc (PBLS) 最新ニュース
Parabilis Medicines Price Insights - YCharts
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine
Top Parabilis Medicines (PBLS) Competitors 2026 - MarketBeat
Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Biotech’s reverse merger renaissance poised to continue - Endpoints News
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView
Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Parabilis Medicines Ord Shs (PBLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Parabilis Medicines, Inc.Common Stock (Nasdaq:PBLS) Stock Quote - The Chronicle-Journal
Alphabet Reports Share Stake In SpaceX, Fervo Energy And Parabilis Medicines - TradingView
Parabilis Medicines (PBLS) Institutional Ownership 2026 - MarketBeat
FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS) - Stock Titan
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts - marketbeat.com
PBLS|Parabilis Medicines Ord Shs|Price:31.820|Chg%:+0.540 - TradingKey
Alexis Borisy: Biotech Is Winning the Science and Losing the Story - finance.biggo.com
Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView
Scribe secures $129M in a rare gene editing IPO - BioPharma Dive
Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo
Form 4 Parabilis Medicines For: 22 July - Investing.com India
Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa
Parabilis Medicines, Inc. (PBLS) Revenue (TTM) - Zacks Investment Research
RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo
With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter
Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha
Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co
Parabilis Medicines Inc (PBLS) 財務データ
Parabilis Medicines Inc (PBLS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Parabilis Medicines Inc (PBLS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 21 '26 |
Buy |
29.25 |
65,923 |
1,928,032 |
26,482,436 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 22 '26 |
Buy |
29.77 |
47,250 |
1,406,632 |
26,529,686 |
| Levy Guy | 10% Owner |
Jun 11 '26 |
Buy |
20.00 |
500,000 |
10,000,000 |
1,027,000 |
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):